A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Trial Profile

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 20 Apr 2016 Results assessing potential clinical biomarkers that correlated with venetoclax sensitivity presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Dec 2014 Interim results in 32 patients presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top